$53.97 Million in Sales Expected for Eagle Pharmaceuticals Inc (EGRX) This Quarter

Wall Street analysts predict that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will post sales of $53.97 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $55.04 million and the lowest is $52.90 million. Eagle Pharmaceuticals posted sales of $46.63 million in the same quarter last year, which suggests a positive year-over-year growth rate of 15.7%. The business is scheduled to report its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full year sales of $231.26 million for the current financial year, with estimates ranging from $219.80 million to $242.72 million. For the next fiscal year, analysts forecast that the company will post sales of $229.20 million, with estimates ranging from $209.70 million to $248.70 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.04. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The company had revenue of $56.05 million for the quarter, compared to analysts’ expectations of $54.17 million. During the same quarter last year, the company earned $1.05 EPS. The firm’s revenue was up 19.8% compared to the same quarter last year.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 23rd. Royal Bank of Canada set a $66.00 price target on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, March 1st. ValuEngine upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, Zacks Investment Research raised Eagle Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a research note on Monday, December 17th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $63.67.

Shares of NASDAQ:EGRX traded up $0.54 on Monday, reaching $49.23. 235,296 shares of the company traded hands, compared to its average volume of 200,514. The stock has a market capitalization of $668.02 million, a P/E ratio of 23.56 and a beta of 1.72. The company has a current ratio of 4.13, a quick ratio of 3.92 and a debt-to-equity ratio of 0.24. Eagle Pharmaceuticals has a 52 week low of $36.03 and a 52 week high of $85.66.

In other Eagle Pharmaceuticals news, CEO Scott Tarriff sold 24,428 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $51.17, for a total value of $1,249,980.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders sold 79,488 shares of company stock worth $3,752,208. Insiders own 28.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. LS Investment Advisors LLC lifted its holdings in Eagle Pharmaceuticals by 97.9% in the 4th quarter. LS Investment Advisors LLC now owns 2,157 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 1,067 shares during the period. Pacer Advisors Inc. lifted its stake in Eagle Pharmaceuticals by 175.4% in the third quarter. Pacer Advisors Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 1,517 shares during the period. Flinton Capital Management LLC lifted its stake in Eagle Pharmaceuticals by 23.9% in the fourth quarter. Flinton Capital Management LLC now owns 2,464 shares of the specialty pharmaceutical company’s stock worth $99,000 after acquiring an additional 476 shares during the period. Neuburgh Advisers LLC lifted its stake in Eagle Pharmaceuticals by 23.9% in the fourth quarter. Neuburgh Advisers LLC now owns 2,992 shares of the specialty pharmaceutical company’s stock worth $121,000 after acquiring an additional 578 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in Eagle Pharmaceuticals by 82.1% in the fourth quarter. Acadian Asset Management LLC now owns 3,008 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 1,356 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Read More: Lock-Up Period Expiration

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.